Akebia Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will present at two investor conferences in November 2025. They will appear at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025 with a fireside chat at 3:00 PM EST, and at the Jefferies Global Healthcare Conference in London on November 17, 2025 with a fireside chat at 12:00 PM GMT.
A webcast of each presentation will be available through the Investors section of Akebia’s website at https://ir.akebia.com following the conferences.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the Nov 4 session, AKBA declined 1.42%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.
Guggenheim Healthcare Innovation Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.
Jefferies Global Healthcare Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.
A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com